Literature DB >> 3731202

Monocyte-mediated drug-dependent cellular cytotoxicity: effects on different WEHI 164 target cell lines.

R Austgulen, O Kildahl-Andersen, T Espevik.   

Abstract

The contribution of monocyte cytotoxic protein factor (CF) to monocyte-mediated drug-dependent cellular cytotoxicity (DDCC) has been investigated. Cell lines which have been derived from murine WEHI 164 cells (termed WEHI 164 parental) by selecting for high (WEHI 164 clone 3) and low (R-WEHI 164) sensitivity to CF-mediated cytotoxicity were used as target cells in DDCC. By comparing the CF doses which produced 50% dead cells (LD 50) we found that WEHI 164 clone 3 was approximately 30 times more sensitive than WEHI 164 parental which in turn was 70 times more sensitive than R-WEHI 164. Actinomycin D (Act D) treatment of WEHI 164 parental and R-WEHI 164 greatly increase susceptibility to CF-mediated cytotoxicity. The susceptibility of WEHI 164 clone 3 was apparently somewhat increased at low dilutions of CF, whereas no significant increase was observed at high dilutions. The susceptibility to DDCC of the three target cell lines (WEHI 164 parental, WEHI 164 clone 3, and R-WEHI 164) correlated with the sensitivity pattern obtained in CF-mediated cytotoxicity of Act D-treated target cells. Monocyte- and CF-mediated cytotoxicity against Act D-treated WEHI 164 clone 3 and R-WEHI 164 was inhibited by neutralizing CF antiserum. These data indicate that CF is an effector molecule in monocyte-mediated DDCC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731202     DOI: 10.1007/bf00200029

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Human monocyte cytotoxic factor mediates cytolysis of WEHI 164 cells.

Authors:  R Austgulen; J Hammerstrøm; T Espevik; J Nissen-Meyer
Journal:  Cell Immunol       Date:  1986-03       Impact factor: 4.868

2.  WEHI 164 sarcoma cells rendered resistant to monocyte-released cytotoxin are also resistant to monocyte-induced cytolysis.

Authors:  O Kildahl-Andersen; R Austgulen; J Nissen-Meyer
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells.

Authors:  M Röllinghoff; N L Warner
Journal:  Proc Soc Exp Biol Med       Date:  1973-12

4.  Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.

Authors:  F Colotta; G Peri; A Villa; A Mantovani
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

5.  The cytotoxic effector cells in preparations of adherent mononuclear cells from human peripheral blood.

Authors:  B Freundlich; G Trinchieri; B Perussia; R B Zurier
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

6.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators.

Authors:  D J Cameron; W H Churchill
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  A rapid assay for cytotoxicity of unstimulated human monocytes.

Authors:  H W Ziegler-Heitbrock; G Riethmüller
Journal:  J Natl Cancer Inst       Date:  1984-01       Impact factor: 13.506

9.  Purification of cytostatic protein factors released from human monocytes.

Authors:  J Nissen-Meyer; O Kildahl-Andersen
Journal:  Scand J Immunol       Date:  1984-10       Impact factor: 3.487

10.  Production and characterization of cytostatic protein factors released from human monocytes during exposure to lipopolysaccharide and muramyl dipeptide.

Authors:  O Kildahl-Andersen; J Nissen-Meyer
Journal:  Cell Immunol       Date:  1985-07       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.